Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 6/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.46 |
| ▸ | RELA | Q04206 | 2/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | FGF23 | Q9GZV9 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9454625 | 0.85 | TSHR (0.52) | NFE2L2PTGS1PTGS2ALOX5RELA | |
| SCHEMBL9335390 | 0.85 | TSHR (0.52) | NFE2L2PTGS1PTGS2ALOX5RELA | |
| SCHEMBL9335412 | 0.85 | TSHR (0.52) | NFE2L2PTGS1PTGS2ALOX5RELA | |
| SCHEMBL11358871 | 0.82 | HDAC4 (0.48) | NFE2L2PTGS1PTGS2ALOX5RELA | |
| SCHEMBL11220909 | 0.82 | HDAC4 (0.48) | NFE2L2PTGS1PTGS2ALOX5RELA | |
| SCHEMBL26316674 | 0.82 | NFE2L2 (0.56) | NFE2L2PTGS1PTGS2ALOX5RELA | |
| SCHEMBL15096127 | 0.82 | RELA (0.57) | NFE2L2PTGS1PTGS2ALOX5RELA | |
| SCHEMBL16080798 | 0.81 | PTGS1 (0.49) | NFE2L2PTGS1PTGS2RELAKDM1A | |
| SCHEMBL15096128 | 0.81 | NFE2L2 (0.52) | NFE2L2PTGS1PTGS2ALOX5RELA | |
| SCHEMBL2749448 | 0.80 | NFE2L2 (0.73) | NFE2L2PTGS1PTGS2ALOX5RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135091-A1 | METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES | US ARMY, SECRETARY OF THE ARMY | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135091-A1 | METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES | HSF1, SIRT1, SIRT2 | NFE2L2 95/4885PTGS1 168/4885PTGS2 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.